ADIL · Adial Pharmaceuticals, Inc.
$3.29
+0.14 (+4.44%)
At close · Jul 30
Going-concern doubt
— flagged May 8, 2026
Substantial doubt about the company's ability to continue as a going concern.
“the Company does not believe that the existing cash and cash equivalents are sufficient to fund operations for the next twelve months following the filing of these unaudited condensed financial statements. During 2026, the Company received net proceeds of approximately $0.3 million from equity issuances. However, the Company will require additional capital to continue operations and development of AD04. These factors raise substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed May 8, 2026
Market Cap
$7.05M
Shares
2.14M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$7.98M
+39.6%
FY2025
Diluted EPS
-$11.93
+82.5%
FY2025
Operating Cash Flow
-$6.49M
+6.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $2.31M | $2.62M | $3.23M | $1.27M | $1.95M | $8.4M | $5.85M | $3.97M | $368.46K | $182.11K | |
| $5.23M | $5.18M | $5.06M | $5.62M | $8.91M | $9.34M | $5.07M | $4.28M | $6.62M | $813.18K | |
| — | $565 | $565 | $564 | $564 | $565 | $564 | $565 | $563 | $565 | |
| $7.53M | $7.8M | $8.28M | $6.89M | $10.86M | $19.29M | $10.93M | $8.24M | $6.99M | $995.29K | |
| — | — | — | — | $550K | — | — | — | — | — | |
| -$7.53M | -$7.8M | -$8.28M | -$6.89M | -$10.86M | -$19.29M | -$10.93M | -$8.24M | -$6.99M | -$995.29K | |
| $161.28K | $149.57K | $178.66K | $69.78K | $63.34K | $6539 | $32.5K | $95.23K | $7392 | $367 | |
| -$237.11K | -$177.71K | -$4.91M | -$113.94K | $63.34K | -$228.68K | $35K | -$346.53K | -$4.64M | -$144.17K | |
| $163.09K | $67.97K | -$552.18K | -$193.88K | — | — | — | — | — | — | |
| — | -$7.98M | -$13.2M | -$7M | -$10.8M | -$19.52M | -$10.89M | -$8.59M | -$11.63M | -$1.14M | |
| — | — | — | — | -$502 | -$94.08K | — | — | — | — | |
| -$7.77M | -$7.98M | -$13.2M | -$5.12M | -$12.73M | -$19.42M | -$10.89M | -$8.59M | -$11.63M | -$1.14M | |
| USD/shares | — | -$11.93 | -$68.01 | -$90.00 | -$317.75 | -$650.00 | — | — | — | — |
| USD/shares | — | -$11.93 | -$68.01 | -$90.00 | -$317.75 | -$650.00 | — | — | — | — |
| shares | — | 668.63K | 194.06K | — | 40.06K | 29.74K | 19.94K | 15.76K | 7614.9808 | 5223.016 |
| shares | — | 668.63K | 194.06K | 56.99K | 40.06K | 29.74K | 19.94K | 15.76K | 389.0912 | 278.8512 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
EV/EBIT
—
P/E (TTM)
—
Peer median 0.04×
Peer medians compare against the 181 similar-size Biotechnology companies (of 522 listed).
Key facts
CIK
1513525
CUSIP
00688A304
13F (30d)
30 filings
5 filers
Visit website
Investor relations